<DOC>
	<DOCNO>NCT00379717</DOCNO>
	<brief_summary>This non-randomized Phase I/II study design determine maximum tolerate dose ( MTD ) thoracic radiotherapy concurrent chemotherapy cisplatin docetaxel patient LA-NSCLC . All patient receive weekly administration docetaxel 20 mg/m² cisplatin 20 mg/m2 concurrently radiotherapy . Radiotherapy deliver use helical tomotherapy 30 daily fraction six week . Patients recover fully induction concurrent chemoradiotherapy continue consolidation chemotherapy phase . Patients enter cohort least 5 subject . The first cohort patient receive 30 fraction 2Gy six week total dose 60Gy . The concurrent chemotherapy start day 1 radiotherapy administer 2-4 hour radiotherapy . The radiotherapy fraction size escalate 2.36Gy three step .</brief_summary>
	<brief_title>Concurrent Helical Tomotherapy With Chemotherapy Unresectable Stage III Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description>Dose escalation step : 30*2.00Gy = 60.0Gy ( BED= 70.8Gy10 NID2= 60.0Gy ) 30*2.12Gy = 63.6Gy ( BED= 75.9Gy10 NID2= 64.2Gy ) 30*2.24Gy = 67.2Gy ( BED= 81.5Gy10 NID2= 68.5Gy ) 30*2.36Gy = 70.8Gy ( BED= 86.3Gy10 NID2= 72.9Gy ) If MTD reach , protocol modification allow escalation consider .</detailed_description>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Informed consent require . 2 . Histologically cytologically confirm NSCLC ( adenocarcinoma , squamous cell carcinoma , large cell carcinoma combination ) 3 . Patients must stage III unresectable LANSCLC : 4 . Males female age 18 75 year . 5 . Life expectancy least 12 week . 6 . ECOG performance status 0,1 or2 . 7 . Weight loss ≤ 10 % within last 3 month . 8 . Laboratory requirement entry : • Blood cell count : . Absolute neutrophils ≥ 2.0 x 109/L ii . Platelets ≥ 100 x 109/L iii . Haemoglobin ≥ 11 g/dl • Renal function : i. Serum creatinine &lt; 1 x upper limit normal ( UNL ) . ii . In case borderline value serum creatinine , 24h creatinine clearance &gt; 60 ml/min . • Hepatic function : i. Serum bilirubin &lt; 1 x UNL ii . ASAT ALAT &lt; 2.5 x UNL iii . alkaline phosphatase &lt; 5 x UNL iv . Patient ASAT and/or ALAT &gt; 1.5 x UNL associate alkaline phosphatase &gt; 2.5 x UNL eligible study . 9 . Lung function test entry : FEV1 : ≥ 50 % x Normal value DLCO : ≥ 50 % x Normal value 10 . Adequate cardiac function . 11 . Patient either measurable and/or nonmeasurable lesion ( accord RECIST criterion , A1 ) . 1 . Diagnosis small cell lung cancer . 2 . Stage IIIB NSCLC , base presence malignant pleural pericardial effusion . 3 . Pregnant lactating woman . 4 . Patients ( male female ) reproductive potential implementing adequate contraceptive measure . 5 . Prior systemic chemotherapy , immunotherapy , biological therapy include neoadjuvant adjuvant treatment NSCLC . 6 . Prior surgery NSCLC , less 5 year study . 7 . Prior radiotherapy NSCLC . 8 . History prior malignancy , except cure nonmelanoma skin cancer , curatively treat insitu carcinoma cervix cancer curatively treat evidence disease least five year . 9 . Symptomatic peripheral neuropathy Grade ≥ 2 except due trauma . 10 . Other serious concomitant illness medical condition : 11 . Congestive heart failure angina pectoris except medically control . Previous history myocardial infarction within 1 year study entry , uncontrolled hypertension arrhythmia . 12 . History significant neurological psychiatric disorder include dementia seizure . 13 . Active infection require IV antibiotic . 14 . Active ulcer , unstable diabetes mellitus contraindication corticosteroid therapy . 15 . Superior vena cava syndrome contraindicate hydration . 16 . Preexisting pericardial effusion . 17 . Preexisting symptomatic pleural effusion . 18 . Significant gastrointestinal abnormality , include requirement intravenous nutrition , active peptic ulcer disease , prior surgical procedure affect absorption . 19 . Distant metastasis . 20 . Concurrent treatment experimental anticancer drug . 21 . Concomitant within 4week period administration experimental drug investigation . 22 . Significant ophthalmologic abnormality . 23 . Moderate severe dermatitis . 24 . Hypersensitivity docetaxel , cisplatin , excipients . 25 . Concomitant use phenytoin , carbamazepin , barbiturate , rifampicin . 26 . Mental condition render patient unable understand nature , scope , possible consequence study . 27 . Patient unlikely comply protocol , i.e. , uncooperative attitude , inability return followup visit , likely complete study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2006</verification_date>
	<keyword>helical tomotherapy</keyword>
	<keyword>dose escalation</keyword>
	<keyword>chemotherapy</keyword>
</DOC>